Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,277 recruiting studies in this area right now.
By phase
- Not applicable9,578
- Phase 24,420
- Phase 12,682
- Phase 1/Phase 21,651
- Phase 31,397
- Phase 2/Phase 3282
- Phase 4267
Top conditions
- Breast Cancer1,205
- Prostate Cancer647
- Cancer637
- Colorectal Cancer481
- Lung Cancer420
- Ovarian Cancer342
- Multiple Myeloma331
- Pancreatic Cancer289
- Gastric Cancer285
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor246
- Advanced Solid Tumor233
- Head and Neck Cancer228
- Cervical Cancer224
- Endometrial Cancer213
- Advanced Solid Tumors206
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University305
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic239
- City of Hope Medical Center148
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca133
- Ruijin Hospital127
Where studies are running
- California1,413
- Texas630
- Arizona510
- Florida434
- Alabama428
- New York407
- Massachusetts340
- Maryland332
- New Jersey275
- Pennsylvania235
Recruiting studies20,277 total
- NCT07105033Recruiting
Focused ACT for advanced cancer patients
This study tests a counseling program called Focused ACT (FACT) to help patients with advanced cancer cope with stress and death anxiety. It involves talking with a counselor about important areas of your life.
Houston, TexasAges 18 years+ - NCT07098182Recruiting
Preserving blood supply during colon or rectal surgery
This trial tests a technique during colon or rectal surgery to preserve a specific blood vessel (the left colic artery) that helps keep the remaining colon healthy. It is for people with left colon, rectal, or ovarian cancer who are scheduled for surgery.
Montpellier, HeraultAges 18 years+ - NCT07104331RecruitingPhase 2
Testing nab-sirolimus for epithelioid hemangioendothelioma
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Stanford, CaliforniaAges 18 years+ - NCT07099391RecruitingPhase 1/Phase 2
Study of two drug combos for newly diagnosed multiple myeloma
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
Basking Ridge, New JerseyAges 18 years+ - NCT07098247Recruiting
Better Imaging for Personalized Radiotherapy
This trial tests a new type of CT scan that might help doctors see tumors more clearly in tricky areas like the brain, head, neck, liver, pancreas, or prostate. It also looks at people with heart disease who need radiation therapy. The goal is to make radiation treatment more accurate and personalized.
Rozzano, MilanAges 18 years+ - NCT07100405Recruiting
TACE plus Immunotherapy for Advanced Liver Cancer
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07101432RecruitingPhase 1
Radiation plus engineered NK cells for advanced head and neck cancer
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
Houston, TexasAges 18 years+ - NCT07096128RecruitingPhase 1
PSMA-targeted radioactive injection for advanced prostate cancer
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07104630RecruitingPhase 2
Pulmonary rehab for advanced lung cancer
This study tests a pulmonary rehabilitation program—special exercises and breathing training—to help people with advanced lung cancer feel less short of breath and improve their daily function and quality of life.
Cleveland, OhioAges 18 years+ - NCT07096362RecruitingPhase 2
Using a blood test to guide treatment for advanced pancreatic cancer
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
Miami, FloridaAges 18 years+ - NCT07100704RecruitingPhase 2
Nivolumab for recurrent olfactory neuroblastoma
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
Kashiwa, ChibaAges 18 years+ - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT07100392RecruitingPhase 2
A new drug combo for advanced liver cancer after first treatment fails
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07102394RecruitingPhase 1
Testing talimogene laherparepvec for skin bumps in adults with NF1
This trial tests a drug called IMLYGIC (talimogene laherparepvec) to see if it is safe and tolerable for treating skin bumps (cutaneous neurofibromas) in adults with NF1. The drug is injected directly into the bumps, and the study will check if it can shrink them or improve symptoms.
Baltimore, MarylandAges 18 years+ - NCT07104812RecruitingPhase 2
Testing low-dose osilodrostat for mild cortisol excess
This study tests whether a low dose of the drug osilodrostat can help people with mild cortisol excess (MACS) caused by benign adrenal tumors. It may improve related health problems like high blood pressure, diabetes, or bone thinning.
Rochester, MinnesotaAges 18 years+ - NCT07096180Recruiting
Integrative Chinese and Western Medicine for Breast Cancer
This study looks at combining traditional Chinese medicine with Western medical care for women with breast cancer. It aims to see how integrative approaches might help people undergoing standard treatments.
New Taipei CityAges 18 years+ - NCT07097155Recruiting
Avocados and cell aging in breast cancer survivors
This study tests whether eating avocados regularly can affect how your cells age. It is for women who have finished treatment for early-stage breast cancer and currently eat fewer than 2 avocados per week.
Reus, TarragonaAges 40–65 - NCT07098299RecruitingPhase 1
Metformin with chemotherapy or immunotherapy for advanced solid tumors
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
Bay City, MichiganAges 18 years+ - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65 - NCT07096999Recruiting
PET scan to plan treatment for prostate cancer
This trial is for men with metastatic castration-resistant prostate cancer who are already scheduled to receive a treatment called Pluvicto. It uses an extra scan (SPECT/CT) to better measure how the treatment reaches the tumors, which could help personalize dosing and improve safety.
Ann Arbor, MichiganAges 18 years+ - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07102589Recruiting
Walking test to measure exercise ability before lung surgery
This trial uses a shuttle walking test to see how well people with chronic lung disease can exercise before and after lung surgery. It may help doctors better understand recovery and plan care.
Seongnam-si, Not Required For This CountryAges 40 years+ - NCT07101497RecruitingPhase 2
BN104 as maintenance therapy after stem cell transplant for leukemia
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Suzhou, JiangsuAges 12 years+ - NCT07105059RecruitingPhase 1
Teclistamab and mezigdomide for multiple myeloma
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
Basking Ridge, New JerseyAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,277 recruiting oncology studies from the U.S. registry right now, out of 30,919 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.